ES2120989T3 - Vector virico recombinante de tipo varicela-zoster. - Google Patents
Vector virico recombinante de tipo varicela-zoster.Info
- Publication number
- ES2120989T3 ES2120989T3 ES92303705T ES92303705T ES2120989T3 ES 2120989 T3 ES2120989 T3 ES 2120989T3 ES 92303705 T ES92303705 T ES 92303705T ES 92303705 T ES92303705 T ES 92303705T ES 2120989 T3 ES2120989 T3 ES 2120989T3
- Authority
- ES
- Spain
- Prior art keywords
- recombinant
- varicela
- virus
- zoster
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000007514 Herpes zoster Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
LA PRESENTE INVENCION SUMINISTRA UN VIRUS RECOMBINANTE DE VARICELA -ZOSTER PREPARADO MEDIANTE LA INSERCION DE AL MENOS UNA CLASE DE UN GEN SELECCIONADO ENTRE UN GRUPO DE GENES DEL GENOMA DEL VIRUS DE LA HEPATITIS B, UN DNA GENOMICO DE DICHO VIRUS RECOMBINANTE, UNA VACUNA EN VIVO QUE CONTIENE DICHO VIRUS RECOMBINANTE COMO INGREDIENTE EFECTIVO, UN ANTIGENO QUE SE ORIGINA DE DICHO VIRUS RECOMBINANTE, Y UN AGENTE DE DIAGNOSTICO QUE CONTIENE DICHO ANTIGENO. EL VIRUS RECOMBINANTE VARICELA TER DE LA PRESENTE INVENCION PUEDE UTILIZARSE COMO UNA VACUNA MULTIVALENTE QUE TIENE UN EFECTO DE INMUNIDAD EXCELENTE TANTO SOBRE LA VIRUELA COMO SOBRE LA HEPATITIS B, Y LOS PRODUCTOS DE EXPRESION Y EL DNA GENOMICO DEL MISMO PUEDE USARSE COMO AGENTE MULTIVALENTE DE DIAGNOSTICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3191340A JP3026029B2 (ja) | 1991-04-26 | 1991-04-26 | 組換え水痘ウイルスとその作製法 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2120989T3 true ES2120989T3 (es) | 1998-11-16 |
Family
ID=16272939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92303705T Expired - Lifetime ES2120989T3 (es) | 1991-04-26 | 1992-04-24 | Vector virico recombinante de tipo varicela-zoster. |
Country Status (11)
Country | Link |
---|---|
US (2) | US5653976A (es) |
EP (1) | EP0510996B1 (es) |
JP (1) | JP3026029B2 (es) |
KR (1) | KR100224331B1 (es) |
AT (1) | ATE171218T1 (es) |
AU (1) | AU659449B2 (es) |
CA (1) | CA2066998C (es) |
DE (1) | DE69226980T2 (es) |
DK (1) | DK0510996T3 (es) |
ES (1) | ES2120989T3 (es) |
TW (1) | TW210354B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9226768D0 (en) * | 1992-12-23 | 1993-02-17 | Smithkline Beecham Biolog | Vaccines |
NZ276102A (en) * | 1993-11-19 | 1998-04-27 | Smithkline Beecham Biolog | Attenuated jeryl-lynn mumps virus strain and vaccines containing it |
FR2719056B1 (fr) * | 1994-04-20 | 1996-09-06 | Rhone Merieux | Herpesvirus transformés pour exprimer gD in vitro. |
US6093535A (en) * | 1996-05-15 | 2000-07-25 | The Research Foundation For Microbial Diseases Of Osaka University | Method for identifying attenuated chickenpox virus Oka strain or strain originating therein and acceptable as attenuated chickenpox vaccine virus |
BR9908599A (pt) * | 1998-03-09 | 2000-11-14 | Smithkline Beecham Biolog | Composições combinadas de vacina |
WO2000050603A1 (fr) * | 1999-02-25 | 2000-08-31 | The Research Foundation For Microbial Diseases Of Osaka University | Gene 62 de la souche oka du virus de la varicelle attenue et procede d'identification de la souche du virus pour le vaccin de la varicelle vivant attenue a l'aide de ce gene |
US6528066B1 (en) * | 1999-09-14 | 2003-03-04 | University Of Iowa Research Foundation | Variant varicella-zoster viruses and methods of use |
UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
EP2471936A3 (en) * | 2005-11-24 | 2013-04-24 | The Research Foundation for Microbial Diseases of Osaka University | Recombinant polyvalent vaccine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0182442B2 (en) * | 1978-12-22 | 1996-04-03 | Biogen, Inc. | Recombinant DNA molecules and their method of production |
JPH0745514B2 (ja) * | 1985-08-20 | 1995-05-17 | 武田薬品工業株式会社 | 新規蛋白質およびその製造法 |
NZ220645A (en) * | 1986-06-20 | 1989-10-27 | Merck & Co Inc | Modified varicella-zoster virus and its cultivation |
US4963483A (en) * | 1987-10-13 | 1990-10-16 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
NZ229260A (en) * | 1988-06-03 | 1994-02-25 | Merck & Co Inc | Hepatitis b virus, expression cassette for pre-s domain, host cells and |
-
1991
- 1991-04-26 JP JP3191340A patent/JP3026029B2/ja not_active Expired - Fee Related
-
1992
- 1992-04-24 AT AT92303705T patent/ATE171218T1/de not_active IP Right Cessation
- 1992-04-24 EP EP92303705A patent/EP0510996B1/en not_active Expired - Lifetime
- 1992-04-24 DE DE69226980T patent/DE69226980T2/de not_active Expired - Lifetime
- 1992-04-24 DK DK92303705T patent/DK0510996T3/da active
- 1992-04-24 CA CA002066998A patent/CA2066998C/en not_active Expired - Fee Related
- 1992-04-24 ES ES92303705T patent/ES2120989T3/es not_active Expired - Lifetime
- 1992-04-25 KR KR1019920007062A patent/KR100224331B1/ko not_active IP Right Cessation
- 1992-04-27 AU AU15214/92A patent/AU659449B2/en not_active Ceased
- 1992-05-22 TW TW081104011A patent/TW210354B/zh active
-
1994
- 1994-11-15 US US08/340,880 patent/US5653976A/en not_active Expired - Lifetime
-
1997
- 1997-03-13 US US08/816,262 patent/US5849476A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5849476A (en) | 1998-12-15 |
EP0510996B1 (en) | 1998-09-16 |
KR920019927A (ko) | 1992-11-20 |
EP0510996A1 (en) | 1992-10-28 |
TW210354B (es) | 1993-08-01 |
AU659449B2 (en) | 1995-05-18 |
DE69226980T2 (de) | 1999-05-12 |
JP3026029B2 (ja) | 2000-03-27 |
JPH06189752A (ja) | 1994-07-12 |
DK0510996T3 (da) | 1999-06-14 |
CA2066998A1 (en) | 1992-10-27 |
ATE171218T1 (de) | 1998-10-15 |
US5653976A (en) | 1997-08-05 |
AU1521492A (en) | 1992-10-29 |
CA2066998C (en) | 2000-05-23 |
KR100224331B1 (ko) | 1999-10-15 |
DE69226980D1 (de) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR010086A1 (es) | Vacuna recombinante aviaria que comprende como vector un virus iltv que comprende y expresa al menos una secuencia nucleotidicaheterologa | |
CY1116761T1 (el) | Αλληλουχιες κυκλοϊου σχετικου με την νοσο απισχνασης του χοιριδιου (map) | |
ES2120989T3 (es) | Vector virico recombinante de tipo varicela-zoster. | |
ES2140418T3 (es) | Flavivirus quimericos y/o flavivirus de crecimiento restringido. | |
DE69737886D1 (de) | Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays | |
CO4700303A1 (es) | Vacuna viva recombinante aviaria que utiliza como vector el virus de la laringotraqueitis infecciosa aviaria | |
ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
CO7160021A2 (es) | Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares | |
ES2166749T3 (es) | Diagnosticos de nanbv: polinucleotidos utiles para discriminar virus de la hepatitis c. | |
ES2089316T3 (es) | Agente viral asociado con la enfermedad porcina misteriosa (mystery swine desease). | |
DE69632235D1 (de) | Newcastle-Krankheitsvirus-Kombinationsimpfstoff | |
RU94038050A (ru) | Рекомбинантный вирус, вектор, вакцина, способ иммунизации, клетка-хозяин | |
ES2061708T3 (es) | Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus. | |
EP1017791A4 (en) | RECOMBINANT RSV VIRUS EXPRESSION SYSTEM AND VACCINES | |
PE20011180A1 (es) | Vacuna contra la salmonella materiales y metodos | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
ES2137160T3 (es) | Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas. | |
DK0431128T3 (da) | Vektor, der koder for selvsamlende, defekte, ikke-selvopformerende viruspartikler | |
BR0206112A (pt) | Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina | |
MX9304349A (es) | Vacuna antirrabica no virulenta. | |
ATE278795T1 (de) | Herpesviren für die modulation einer immunantwort | |
AR031599A1 (es) | Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz | |
Wong et al. | Systemic toll-like receptor ligation and selective killing of dendritic cell subsets fail to dissect priming pathways for anti-vaccinia virus CD8+ T cells | |
CY1105176T1 (el) | Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας | |
ES2062990T3 (es) | Vacunas, que contienen la proteina f del virus del sida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 510996 Country of ref document: ES |